‘Game-changer’ GLP-1s could fix America’s obesity crisis—but 2 inequalities stand in the way | Fortune0

• bond-market, Business, Business / Artificial Intelligence, Business / Big Tech, Business / Companies, Business / Computers and Software, Business / Markets, Business / Social Media, business-idea, business-insider-today, business-strategy, CoECI News, E! Insider, Energy & Environment Newsletter, Finance, Gaming News Roundup, Gear / Gear News and Events, Global, Global Precipitation, global warming, globalstar, HEALTH, Home, House, insider-picks, insider-picks-guides, insider-reviews, insider-reviews-2021, insider-today, job-market, LIFESTYLE, Markets, Markets & Festivals, News, newsletter, Newsletters, Nexstar Media Wire News, People News, Personal Finance, personal-finance, Photovogue / Editorial / News, Politics / Politics News, Property / News, Reviews, reviews-rit-ads, Security / Security News, shop, Shop Beauty
• August 20, 2026

For roughly 40% of American adults living with obesity, the medical playbook has barely changed in decades: Eat less, move more, and if that fails, wait until the disease progresses far enough to justify surgery. GLP-1 drugs like Ozempic, Wegovy, and Zepbound have broken that script—but according to Robin Wenzel, head of Wells Fargo Industry